Mineralys Therapeutics, Inc. $MLYS Stake Lessened by SR One Capital Management LP

SR One Capital Management LP lowered its holdings in shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) by 32.4% during the third quarter, HoldingsChannel.com reports. The firm owned 2,113,933 shares of the company’s stock after selling 1,014,000 shares during the period. Mineralys Therapeutics makes up approximately 11.6% of SR One Capital Management LP’s holdings, making the stock its 4th largest holding. SR One Capital Management LP’s holdings in Mineralys Therapeutics were worth $80,160,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in MLYS. AQR Capital Management LLC purchased a new position in shares of Mineralys Therapeutics during the 1st quarter valued at approximately $550,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Mineralys Therapeutics by 4.3% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 17,085 shares of the company’s stock worth $271,000 after acquiring an additional 702 shares during the period. Goldman Sachs Group Inc. lifted its holdings in Mineralys Therapeutics by 166.6% during the first quarter. Goldman Sachs Group Inc. now owns 298,395 shares of the company’s stock valued at $4,739,000 after purchasing an additional 186,480 shares in the last quarter. Woodline Partners LP acquired a new stake in shares of Mineralys Therapeutics in the first quarter valued at about $757,000. Finally, Y Intercept Hong Kong Ltd acquired a new stake in shares of Mineralys Therapeutics in the second quarter valued at about $288,000. 84.46% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the stock. Stifel Nicolaus raised their price target on shares of Mineralys Therapeutics from $45.00 to $52.00 and gave the company a “buy” rating in a research note on Friday, December 19th. Wells Fargo & Company raised their target price on Mineralys Therapeutics from $50.00 to $55.00 and gave the company an “overweight” rating in a research report on Tuesday, November 11th. HC Wainwright boosted their price target on Mineralys Therapeutics from $52.00 to $56.00 and gave the stock a “buy” rating in a research report on Wednesday, November 12th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Mineralys Therapeutics in a report on Thursday, January 22nd. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $47.43.

Mineralys Therapeutics Stock Down 7.1%

NASDAQ MLYS opened at $26.72 on Friday. The business’s fifty day simple moving average is $31.54 and its 200-day simple moving average is $34.85. The firm has a market cap of $2.11 billion, a PE ratio of -9.06 and a beta of 0.57. Mineralys Therapeutics, Inc. has a 52 week low of $9.69 and a 52 week high of $47.65.

Insider Activity

In other Mineralys Therapeutics news, insider David Malcom Rodman sold 192,715 shares of the company’s stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $35.02, for a total value of $6,748,879.30. Following the transaction, the insider owned 61,804 shares of the company’s stock, valued at $2,164,376.08. This represents a 75.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CFO Adam Scott Levy sold 10,758 shares of the stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $32.14, for a total transaction of $345,762.12. Following the transaction, the chief financial officer directly owned 8,638 shares of the company’s stock, valued at approximately $277,625.32. This trade represents a 55.47% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 340,748 shares of company stock valued at $11,697,169 in the last quarter. Insiders own 25.56% of the company’s stock.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.